Jean-christophe Delumeau PhD

Jean-Christophe Delumeau graduated in medicine, toxicology, pharmacology, applied statistics and methodology of clinical trials, from universities of Rennes and Paris. From 1986, after completing residency, he joined Jacques Glowinski's laboratory, part of the French national institute of medical research (inserm), at the College de France in Paris. There, he developed microfluorimetry i.e. the use fluorescent probes for monitoring the concentrations of intracellular calcium in single cells, contributing to a research program aimed at exploring the different components of intracellular signaling. This fundamental research work resulted in a Ph.D at the University Pierre and Marie Curie (Paris VI) in 1991. In parallel the technique was transferred to pharma industry research to investigate the mechanism CNS drugs such as riluzole.
Afterwards Jean-Christophe Delumeau joined the pharmaceutical industry working in international clinical research, in Basel (Hoffmann-La Roche, Novartis), Paris and Tokyo (Rhone-Poulenc Rorer). At Rhone-Poulenc Rorer, he conducted the multinational trial which confirmed the efficacy of an antiglutamate agent in amyotrophic lateral sclerosis, which trial resulted in the global approval of riluzole in this devastating disease. Afterwards, at Novartis, he continued to worke in the field of neurodegenerative diseases, especially Parkinson's disease.
Jean-Christophe Delumeau was appointed by Bayer Yakuhin in Osaka, to support implementing a global reengineering program. From 2002 until 2009, he headed Bayer Yakuhin’s Pharmacovigilance department in charge of Drug Safety, Postmarketing Studies and Labeling. In October 2009, he was appointed as head of Pharmacovigilance for Asia-Pacific, based at Bayer Healthcare’s global development center in Beijing